Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
Figg
W D
WD
Developmental Therapeutics Department, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Feuer
J A
JA
Bauer
K S
KS
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D018931:Antineoplastic Agents, Hormonal / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000556:secondary
D018931:Antineoplastic Agents, Hormonal